Stockscreener 앱 받기
8.81
0.12%
-0.011
시간 외 거래:
8.81
전일 마감가:
$8.821
열려 있는:
$8.81
하루 거래량:
15,147
Relative Volume:
0.28
시가총액:
$174.22M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
-2.44%
1개월 성능:
+8.63%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$8.39
$8.92
1주일 범위
$8.39
$9.9499
52주 변동 폭
$5.51
$11.73
Actuate Therapeutics Inc Stock (ACTU) Company Profile
명칭
Actuate Therapeutics Inc
전화
847-986-4190
주소
1751 RIVER RUN, FORT WORTH
ACTU을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ACTU
Actuate Therapeutics Inc
|
8.81 | 174.22M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.32 | 122.13B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
710.00 | 78.30B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
646.64 | 39.73B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
276.19 | 35.50B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.61 | 28.47B | 3.30B | -501.07M | 1.03B | -2.1146 |
Actuate Therapeutics Inc 주식(ACTU)의 최신 뉴스
Actuate Therapeutics sets annual meeting for May 22 - Investing.com India
Actuate Therapeutics' Lock-Up Period Will Expire on February 10th (NASDAQ:ACTU) - MarketBeat
Actuate Therapeutics to Participate in Upcoming Investor Conferences in February - GlobeNewswire
Ataxia Telangiectasia Market on Track for Major Expansion by 2032, According to DelveInsight | Acasti Pharma Inc., IntraBio Inc - The Globe and Mail
Actuate Therapeutics’ (NASDAQ:ACTU) Lock-Up Period Set To Expire on February 10th - Defense World
Actuate Therapeutics (NASDAQ:ACTU) Trading Down 5.4%Here's What Happened - MarketBeat
Trump 2.0: This Sector May See A Big Performance Boost - The Globe and Mail
Algonquin Power & Utilities Corp. Announces Leadership Transition - The Globe and Mail
Myelofibrosis Clinical Trials, Pipeline Analysis, EMA, PDMA, - openPR
Meta Platforms Is Surging on Q4 Earnings. Is Meta Stock a Buy, Sell, or Hold for 2025? - The Globe and Mail
Bone metastasis in Solid Tumor Market Expected to rise, 2034 | Mabwell Bioscience Co., Novartis, Institut Bergonié, Pfizer, GlaxoSmithKline, Amgen, QSAM Therapeutics, Actuate Therapeutics - Barchart
Earnings To Watch: Kirby (KEX) Reports Q4 Results Tomorrow - The Globe and Mail
Bone metastasis in Solid Tumor Market Expected to rise, 2034 | - openPR
TOROMONT TO ANNOUNCE 2024 FULL YEAR AND FOURTH QUARTER RESULTS ON FEBRUARY 11, 2025 - The Globe and Mail
Why IMAC Holdings Shares Are Trading Higher By Over 108%; Here Are 20 Stocks Moving Premarket - Benzinga
The Best High-Yield Energy Stock to Invest $200 in Right Now - The Globe and Mail
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
3 Artificial Intelligence (AI) Stocks That Could Go on a Multidecade Run - The Globe and Mail
Pre-market Movers: SAGE, ITCI, GCTK, MRNA... - RTTNews
EMA gives OMPD to Actuate’s pancreatic cancer therapy - MSN
Here's How Much Money You'd Have if You Invested $10,000 in Nvidia a Decade Ago - The Globe and Mail
Actuate Therapeutics (NASDAQ:ACTU) Shares Down 2.1%What's Next? - MarketBeat
EMA grants orphan drug designation to Actuate's cancer drug - Investing.com
Actuate Therapeutics Receives EMA Orphan Medicinal Product - GlobeNewswire
Actuate Therapeutics Receives EMA Orphan Medicinal Product Designation for Elraglusib for the Treatment of Pancreatic Cancer - Yahoo Finance
Is Raytheon the Best Defense and Aerospace Stock to Own in 2025? - The Globe and Mail
Elraglusib can prolong survival in metastatic pancreatic cancer: Trial - Myeloma Research News
Pancreatic Cancer Market Growth Projections 2024-2034: DelveInsight Analysis - EIN News
Actuate reports breakthrough in pancreatic cancer trial By Investing.com - Investing.com South Africa
Actuate sees 37% cut in risk of death in Phase II pancreatic cancer trial - Yahoo Finance
Actuate reports breakthrough in pancreatic cancer trial - Investing.com
Actuate Therapeutics Shares Rise 12% on Positive Phase 2 Trial to Treat Metastatic Pancreatic Ductal Cancer - MarketWatch
Actuate Therapeutics Announces Positive Interim Phase 2 - GlobeNewswire
Actuate's Pancreatic Cancer Drug Shows Breakthrough 44% One-Year Survival Rate in Phase 2 Trial - StockTitan
Actuate Therapeutics (NASDAQ:ACTU) Trading 0.8% HigherShould You Buy? - MarketBeat
Pre-market Movers: EWTX, TNXP, LNSR, VRDN... - RTTNews
Why RH Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket - Benzinga
Ewing Sarcoma Treatment Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Therapies, Patient Pool, Prevalence and Companies DelveInsight - The Globe and Mail
GXO Logistics: Time to Buy the Dip for the Rip in 2025 - The Globe and Mail
Actuate Therapeutics to be Added to Russell 2000® Index - The Manila Times
Actuate Therapeutics, oncology drug developer, sets terms for $50M IPO - MSN
Myelofibrosis Market to Show Remarkable Growth Trends from 2023 to 2032, DelveInsight Reports | Lynk Pharma, Samus Therapeutics, Taiga Biotech, Bristol-Myers Squibb, Sumitomo Pharma Oncology, Keros - Barchart
Palantir vs. Tesla: Which Growth Stock is a Better Buy Right Now? - The Globe and Mail
Mirdametinib Boosts Outcomes, QOL in NF1-PN - www.oncnursingnews.com/
FDA OKs Ninlotinib Tablets With No Mealtime Restrictions for CML - www.oncnursingnews.com/
FDA Grants Rare Pediatric Designation to Elraglusib for Ewing Sarcoma - www.oncnursingnews.com/
FDA grants rare disease status to Actuate's Ewing sarcoma drug By Investing.com - Investing.com Australia
FDA grants rare disease status to Actuate's Ewing sarcoma drug - Investing.com India
Actuate Therapeutics : FDA Grants Pediatric-Disease Status to Ewing Sarcoma Treatment - Marketscreener.com
Actuate Therapeutics: FDA Grants Pediatric-Disease Status to Ewing Sarcoma Treatment - MarketWatch
Actuate Announces FDA Rare Pediatric Disease Designation Granted to Elraglusib for Treatment of Ewing Sarcoma - The Manila Times
Actuate Therapeutics Inc (ACTU) 재무 분석
Actuate Therapeutics Inc (ACTU)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
Actuate Therapeutics Inc 주식 (ACTU) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Bios Equity COF, LP | Director |
Aug 14 '24 |
Buy |
8.00 |
500,000 |
4,000,000 |
1,259,427 |
| Bios Equity COF, LP | Director |
Aug 14 '24 |
Sale |
9.00 |
24,999 |
224,991 |
131,248 |
| Fletcher Aaron G.L. | Director |
Aug 14 '24 |
Buy |
8.00 |
500,000 |
4,000,000 |
1,259,427 |
| Fletcher Aaron G.L. | Director |
Aug 14 '24 |
Sale |
9.00 |
24,999 |
224,991 |
131,248 |
| Kreis Leslie W. | 10% Owner |
Aug 14 '24 |
Buy |
8.00 |
500,000 |
4,000,000 |
1,259,427 |
| Kreis Leslie W. | 10% Owner |
Aug 14 '24 |
Sale |
9.00 |
24,999 |
224,991 |
131,248 |
1.09%
자본화:
|
볼륨(24시간):